33453-98-4

Usage

Uses

Used in Pharmaceutical Synthesis:
N-(2-NITROISOTUTYL)-MORPHOLINE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new medicinal compounds.
Used in Organic Compounds Synthesis:
It serves as an intermediate in the synthesis of various organic compounds, facilitating the creation of a range of chemical products.
Used in Metalworking Fluids:
N-(2-NITROISOTUTYL)-MORPHOLINE is used as a corrosion inhibitor in metalworking fluids, helping to prevent the deterioration of metal parts and tools during manufacturing processes.
Used in Industrial Product Stabilization:
N-(2-NITROISOTUTYL)-MORPHOLINE acts as a stabilizer in industrial products to enhance their longevity and performance, ensuring they maintain their properties over time.
Used in Antimicrobial Applications:
Due to its antimicrobial properties, N-(2-NITROISOTUTYL)-MORPHOLINE can be utilized in applications where the inhibition of microbial growth is required, such as in certain types of coatings or treatments for surfaces prone to microbial colonization.

InChI:InChI=1/C8H16N2O3/c1-8(2,10(11)12)7-9-3-5-13-6-4-9/h3-7H2,1-2H3

Upstream product

• 110-91-8 morpholine 
• 76-39-1 2-nitro-2-methylpropanol 
• 79-46-9 2-nitropropane 
• 5472-71-9 1-(4-morpholinomethyl)-1H-benzotriazole 
• 24163-39-1 sodium 2-nitropropane 
• 50-00-0 formaldehyd 

Downstream Products

• 6105-75-5 2-methyl-1-(morpholin-4-yl)propan-2-amine 

Relevant academic research and scientific papers

Polycyclic derivatives and preparation thereof

The invention discloses compounds shown as a formula (I) and a formula (II) and stereoisomers, pharmaceutically acceptable salts, solvates, hydrates, N-oxides and prodrugs thereof, pharmaceutical compositions and preparation methods of the compounds and t

NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

Storage stable perfusion solution for dihydropteridinones

Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.

New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to new dihydropteridinones of general formula (I) wherein the groups L and R1- R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropterid

THE CHEMISTRY OF N-SUBSTITUTED BENZOTRIAZOLE. REACTIONS OF N-(α-AMINOALKYL)- AND N-(α-AMIDOALKYL)-BENZOTRIAZOLES WITH MONODEPROTONATED NITROALKANES

N-(β-Nitroalkyl)amines 1a-i and N-(β-nitroalkyl)amides 1j-n are easily prepared by the C-amino(amido)alkylation of simple alkyl nitronate anions 3a-c with adducts 2a-i.The adducts themselves are readily available from one molecule each of an amine (or ami